72
Participants
Start Date
December 12, 2023
Primary Completion Date
April 24, 2026
Study Completion Date
July 24, 2026
AK132
IV infusion, specified dose on specified days.
Fujian Provincial Cancer Hospital, Fuzhou
Hunan Provincial Cancer Hospital, Changsha
Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital, Wuhan
Xiangyang Central Hospital, Xiangyang
Sun Yat-Sen University Cancer Center, Guangzhou, China, Guangzhou
Southern Medical University Nanfang Hospital, Guangzhou
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Lead Sponsor
Akeso
INDUSTRY